DSM will invest EUR 7 million in the basic engineering for a new biopharmaceutical plant in Canada. The new multi-product facility will comprise four fermentors with a combined capacity of more than 60,000 litres and will also include downstream processing and all necessary infrastructure. It will be used for the production of monoclonal antibodies (MABs) and recombinant proteins based on mammalian cell culture technology. These are a new generation of drugs representing a strongly growing segment of the pharmaceutical industry.
The plant, to be located in Montreal (Quebec) in Canada, will have a modular design, with two production lines of about 30,000 litres each. This makes it possible to adapt or expand the plant depending on the processes to be operated in it and the needs of the market. The new high-tech plant represents a large-scale expansion of DSM Biologics’ R&D and production facilities in Montreal. “The decision reflects DSM’s strategic choice to make further investments in the Life Science industry in general and in biotechnology/biopharma in particular,” says Gerben Algra, Managing Director of DSM Biologics. “This proposed expansion will also be a major step forward in the realisation of DSM Biologics’ growth mission to become a world market leader in the contract manufacture of biopharmaceutical products, and it means a strengthening of DSM’s leading position as a supplier to the pharma industry.”
For more projects, subscribe to our Project Preview Newsletter
